105 results on '"Waters, David D."'
Search Results
2. Usefulness of Angina to Guide Revascularization Decisions
3. Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial
4. Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib.
5. HIV infection and coronary heart disease: mechanisms and management
6. High plasma FGF21 levels predicts major cardiovascular events in patients treated with atorvastatin (from the Treating to New Targets [TNT] Study).
7. Variations in time to benefit among clinical trials of cholesterol-lowering drugs.
8. Visit-to-visit variability of lipid measurements as predictors of cardiovascular events.
9. Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk.
10. Cholesterol Lowering Guidelines: From Whence We Came and Where We Are Now
11. Lipid Abnormalities in Persons Living With HIV Infection
12. Will Colchicine Soon Be Part of Primary and Secondary Cardiovascular Prevention?
13. When Diastole Lets You Down: Clinical Relevance of a Widened Pulse Pressure
14. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial
15. An Evidence-Based Guide to Cholesterol-Lowering Guidelines
16. Predicting Prognosis in Acute Coronary Syndromes: Makeover Time for TIMI and GRACE?
17. Cardiovascular drugs that increase the risk of new-onset diabetes.
18. Time to Recognize HIV Infection as a Major Cardiovascular Risk Factor
19. Taking Hockey to Heart: Potential Coronary Risks of Watching Exciting Games
20. LDL-cholesterol lowering and renal outcomes
21. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials
22. The Past and Future of Heart Institutes: Having Moved Beyond the One-Trick Pony
23. Vitamin D levels do not predict cardiovascular events in statin-treated patients with stable coronary disease.
24. The 719Arg Variant of KIF6 and Cardiovascular Outcomes in Statin-Treated, Stable Coronary Patients of the Treating to New Targets and Incremental Decrease in End Points Through Aggressive Lipid-Lowering Prospective Studies.
25. Notes From Cardiology Clinic: Mitral Stenosis and Racial Discordance
26. Exploring new indications for statins beyond atherosclerosis: Successes and setbacks.
27. Low- and high-density lipoprotein cholesterol goal attainment in dyslipidemic women: The Lipid Treatment Assessment Project (L-TAP) 2.
28. Clinical Insights From the Treating to New Targets Trial.
29. The Atorvastatin/Donepezil in Alzheimer’s Disease Study (LEADe): Design and baseline characteristics ⁎ [⁎] Roy W. Jones and Miia Kivipelto contributed equally to the content of the manuscript.
30. Effects of Statin Therapy on the Development and Progression of Heart Failure: Mechanisms and Clinical Trials.
31. Chlamydia Pneumoniae and Atherosclerosis: From Koch Postulates to Clinical Trials.
32. The Evolution of Myocardial Infarction: When the Truths We Hold To Be Self-Evident No Longer Have Evidence
33. The Rise and Fall of Tuberculosis and Atherosclerosis: First There Is a Mountain…
34. Performance Deficiencies in the Treatment of ST-Elevation Myocardial Infarction in Québec: “Tis But a Part We See, and Not a Whole”
35. Notes From Cardiology Clinic: Trouble for Tongans
36. Notes From Cardiology Clinic: The Heartbreaking Risk Factor We Overlook
37. Papering Over the Cracks: Meta-analysis to Define the Role of Percutaneous Coronary Intervention in Patients With Stable Angina
38. Utility of Biomarkers and Imaging in the Development of Drugs for the Treatment of Coronary Atherosclerosis
39. The 719Arg Variant of KIF6 and Cardiovascular Outcomes in Statin-Treated, Stable Coronary Patients of the Treating to New Targets and Incremental Decrease in End Points Through Aggressive Lipid-Lowering Prospective Studies
40. Tobacco smoke and cardiovascular risk
41. Tribulations of Recent Cardiology Trials, the Audacity of Hope, and HOPE-3
42. A winter’s tale: Report from the First Annual Canadian Biomarkers and Surrogate Endpoints Symposium
43. Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2(PLASMA study): a phase II double-blind, randomised, placebo-controlled trial
44. Notes From Cardiology Clinic: Health Care Heroine, Unpaid and Unappreciated
45. Notes From Cardiology Clinic: Brittle Bones and Blue Sclerae
46. Notes From the Cardiology Clinic: Facing Down the Dragons of Health Anxiety
47. Notes From Cardiology Clinic: The Patients We Dislike
48. WITHDRAWN: Notes From Cardiology Clinic: The Patients We Dislike
49. Notes From Cardiology Clinic: Woman, Lost During Follow-up
50. American College of Cardiology/Society for Cardiac Angiography and Interventions Clinical Expert Consensus Document on Cardiac Catheterization Laboratory Standards41When citing this document, the American College of Cardiology and the Society for Cardiac Angiography and Interventions would appreciate the following citation format: Bashore TM, Bates ER, Berger PB, Clark DA, Cusma JT, Dehmer GJ, Kern MJ, Laskey WK, O’Laughlin MP, Oesterle S, Popma JJ. Cardiac catheterization laboratory standards: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents (ACC/SCA&I Committee to Develop an Expert Consensus Document on Cardiac Catheterization Laboratory Standards). J Am Coll Cardiol 2001;37:2170–214.44Address for reprints: This document is available on the Web sites of the American College of Cardiology (http://www.acc.org) and the Society for Cardiac Angiography and Interventions (http://www.scai.org). Reprints of this document may be purchased for $5
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.